Peptides and proteins used to enhance gold nanoparticle delivery to the brain: preclinical approaches
Author
dc.contributor.author
Velasco Aguirre, Carolina
Author
dc.contributor.author
Morales, Francisco
Author
dc.contributor.author
Gallardo Toledo, Eduardo
Author
dc.contributor.author
Guerrero, Simón
Author
dc.contributor.author
Giralt, Ernest
Author
dc.contributor.author
Araya, Eyleen
Author
dc.contributor.author
Kogan Bocian, Marcelo
Admission date
dc.date.accessioned
2015-11-05T18:26:04Z
Available date
dc.date.available
2015-11-05T18:26:04Z
Publication date
dc.date.issued
2015
Cita de ítem
dc.identifier.citation
International Journal of Nanomedicine 2015:10
en_US
Identifier
dc.identifier.other
DOI: 10.2147/IJN.S82310
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/134865
General note
dc.description
Artículo de publicación ISI
en_US
Abstract
dc.description.abstract
An exciting and emerging field in nanomedicine involves the use of gold nanoparticles (AuNPs) in the preclinical development of new strategies for the treatment and diagnosis of brain-related diseases such as neurodegeneration and cerebral tumors. The treatment of many brain-related disorders with AuNPs, which possess useful physical properties, is limited by the blood-brain barrier (BBB). The BBB highly regulates the substances that can permeate into the brain. Peptides and proteins may represent promising tools to improve the delivery of AuNPs to the central nervous system (CNS). In this review, we summarize the potential applications of AuNPs to CNS disorders, discuss different strategies based on the use of peptides or proteins to improve the delivery of AuNPs to the brain, and examine the intranasal administration route, which bypasses the BBB. We also analyze the potential neurotoxicity of AuNPs and the perspectives and new challenges concerning the use of peptides and proteins to enhance the delivery of AuNPs to the brain. The majority of the work described in this review is in a preclinical stage of experimentation, or in select cases, in clinical trials in humans. We note that the use of AuNPs still requires substantial study before being translated into human applications. However, for further clinical research, the issues related to the potential use of AuNPs must be analyzed.